Unity Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

Unity Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

Unity Biotechnology, Inc. reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 98.58% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2025-03-07

• Unity Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 98.58%, a 0.34% decline from fiscal 2023.
• Unity Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 98.92%, a 6.17% increase from fiscal 2022.
• Unity Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 93.17%, a 5.28% increase from fiscal 2021.
• Unity Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 88.50%, a 17.98% decline from fiscal 2020.